Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coley’s ProMune shows promise in lung cancer
The randomized, controlled phase II study was designed to evaluate improved response when ProMune is added to standard chemotherapy compared to chemotherapy alone, in first-line treatment of advanced
The randomized, controlled phase II study was designed to evaluate improved response when ProMune is added to standard chemotherapy compared to chemotherapy alone, in first-line treatment of advanced
The preliminary 48-week data is from Gilead’s Study 934, a phase III trial designed to compare a regimen of Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Sustiva (efavirenz)
A letter from Professor G. Duff, chairman of the Committee on Safety of Medicines, advised doctors and patients of the risk of incurring rare, but sometimes severe, liver
VP025 is being developed to target the chronic inflammation within the central nervous system that is associated with a number of neurological diseases, including Alzheimer’s disease, Parkinson’s disease,
The results showed that Procyon’s PL-100 and its back-up analogue PL-337 had the most favorable cross-resistance profile of all the protease inhibitors (PIs) studied, as measured by the
ViroLogic’s novel HIV resistance testing technology will be used across GSK’s virology portfolio, including its entry inhibitor program, where a ViroLogic assay will be used to identify patients
Antisoma is evaluating options for the further development of Aptamera’s lead product, AGRO100, which is now redesignated AS1411. The next step will be either a phase II study
Intendis management introduced the new company and its growth prospects at a press conference in Berlin, Germany. The company plans to invest in the marketing of the group’s
These compounds are the first to be invented by Speedel Experimenta, the company’s late-stage research unit, which was established in 2002. SPP630 and SPP635 have now been successfully
Ceftobiprole has activity against methicillin-resistant Staphylococcus aureus (MRSA) and is in phase III clinical trials in complicated skin and skin structure infections, with hospital-acquired pneumonia trials also in